News

Phanes Therapeutics' PT217 receives Orphan Drug Designation for small cell lung cancer from the FDA

Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and clinical development in oncology, announced...

36Kr Venture Capital Research Institute, along with the “X·36under36” S-level young entrepreneurs launched in early June, launched a...

Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and clinical development in immuno-oncology...

The Shanghai-based medtech business has received RMB 400million (£46.9million) in Series D funding, led by SoftBank Vision Fund 2 and...

Since 2001, Zero2IPO Research Center has published the annual ranking of China's equity investment for 21 consecutive years, adhering to...

Volcanics Venture awarded with "Top 100 Most Popular Investment Institutions for Entrepreneurs in China" by 36Kr, "China's Most Admired...

Tech company Fourier Intelligence receives tens of millions in a new round of financing to accelerate the construction of the...

RootPath Genomics, a preclinical-stage biotech firm that develops personalised immunotherapy and cell therapy for solid tumours, has...

Originally witten in Chinese by Wang Zhichen Source: kouailiyu (Wechat ID: akuailiyu) Recently, Huleen announced the closing of angel...

Original from prnasia NANJING, China, June 24, 2021 /PRNewswire/ -- Triastek, Inc. (Triastek), a global leader in 3D printed...